Comerica Bank’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $3.89M | Sell |
27,450
-2,142
| -7% | -$310K | 0.02% | 747 |
|
|
2025
Q3 | $4.15M | Sell |
29,592
-2,233
| -7% | -$303K | 0.02% | 789 |
|
|
2025
Q2 | $4M | Buy |
31,825
+106
| +0.3% | +$12.2K | 0.02% | 776 |
|
|
2025
Q1 | $3.51M | Sell |
31,719
-1,727
| -5% | -$219K | 0.01% | 834 |
|
|
2024
Q4 | $4.57M | Sell |
33,446
-1,395
| -4% | -$173K | 0.02% | 727 |
|
|
2024
Q3 | $4.01M | Sell |
34,841
-117,983
| -77% | -$16.2M | 0.02% | 801 |
|
|
2024
Q2 | $21M | Buy |
152,824
+17,178
| +13% | +$2.36M | 0.09% | 213 |
|
|
2024
Q1 | $18.7M | Sell |
135,646
-14,778
| -10% | -$2.02M | 0.08% | 240 |
|
|
2023
Q4 | $19.8M | Sell |
150,424
-5,058
| -3% | -$582K | 0.09% | 202 |
|
|
2023
Q3 | $17.5M | Buy |
155,482
+137,338
| +757% | +$14.5M | 0.09% | 201 |
|
|
2023
Q2 | $60 | Buy |
+18,144
| New | +$1.77M | 0.01% | 165 |
|
|
2022
Q4 | $9.68M | Sell |
89,412
-25,890
| -22% | -$3.03M | 0.08% | 288 |
|
|
2022
Q3 | $12.7M | Sell |
115,302
-9,619
| -8% | -$976K | 0.11% | 174 |
|
|
2022
Q2 | $12M | Sell |
124,921
-10,775
| -8% | -$994K | 0.1% | 191 |
|
|
2022
Q1 | $13.3M | Sell |
135,696
-23,002
| -14% | -$1.95M | 0.1% | 192 |
|
|
2021
Q4 | $12.1M | Buy |
158,698
+12,079
| +8% | +$1.11M | 0.09% | 217 |
|
|
2021
Q3 | $15.2M | Buy |
146,619
+1,889
| +1% | +$178K | 0.09% | 206 |
|
|
2021
Q2 | $13M | Buy |
144,730
+29,856
| +26% | +$2.86M | 0.08% | 244 |
|
|
2021
Q1 | $11.1M | Buy |
114,874
+73,869
| +180% | +$7.75M | 0.07% | 314 |
|
|
2020
Q4 | $4.79M | Buy |
41,005
+21,933
| +115% | +$2.12M | 0.03% | 722 |
|
|
2020
Q3 | $1.89M | Buy |
19,072
+4,200
| +28% | +$486K | 0.01% | 1160 |
|
|
2020
Q2 | $1.94M | Sell |
14,872
-3,427
| -19% | -$379K | 0.01% | 1099 |
|
|
2020
Q1 | $1.8M | Buy |
18,299
+14,021
| +328% | +$1.37M | 0.02% | 984 |
|
|
2019
Q4 | $434K | Buy |
4,278
+345
| +9% | +$36.1K | ﹤0.01% | 1950 |
|
|
2019
Q3 | $386K | Buy |
3,933
+125
| +3% | +$11.7K | ﹤0.01% | 1972 |
|
|
2019
Q2 | $335K | Sell |
3,808
-10,848
| -74% | -$891K | ﹤0.01% | 2031 |
|
|
2019
Q1 | $1.34M | Buy |
14,656
+6,002
| +69% | +$502K | 0.01% | 1392 |
|
|
2018
Q4 | $736K | Buy |
8,654
+5,549
| +179% | +$532K | 0.01% | 1709 |
|
|
2018
Q3 | $337K | Sell |
3,105
-159
| -5% | -$18K | ﹤0.01% | 2024 |
|
|
2018
Q2 | $341K | Sell |
3,264
-20
| -0.6% | -$1.79K | ﹤0.01% | 2036 |
|
|
2018
Q1 | $257K | Sell |
3,284
-46
| -1% | -$3.88K | ﹤0.01% | 2116 |
|
|
2017
Q4 | $295K | Sell |
3,330
-46
| -1% | -$3.14K | ﹤0.01% | 2094 |
|
|
2017
Q3 | $210K | Buy |
+3,376
| New | +$178K | ﹤0.01% | 2165 |
|
Other funds holding NBIX
Comerica Bank's NBIX Position: Q4 2025 in Review
Comerica Bank reduced its Neurocrine Biosciences (NBIX) stake by 7.2% in Q4 2025, selling an estimated $310K and leaving 27,450 shares worth $3.89M. The position accounts for 0.02% of the portfolio, ranked #747.
Comerica Bank first reported a position in NBIX in Q3 2017 and has held it in 33 quarters since. The position peaked at $21M in Q2 2024. 731 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.
- Comerica Bank held 27,450 shares of Neurocrine Biosciences worth $3.89M as of Q4 2025.
- Comerica Bank sold 2,142 Neurocrine Biosciences shares in Q4 2025, an estimated $310K.
- Neurocrine Biosciences made up 0.02% of Comerica Bank's portfolio in Q4 2025, its #747 holding.
- Comerica Bank first reported a position in Neurocrine Biosciences in Q3 2017 and has held it in 33 quarters since.
- Comerica Bank's Neurocrine Biosciences position peaked at $21M in Q2 2024.
- 731 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.
Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.